PonatinibDevelopment of resistance: 3 case reports

被引：0

作者：

机构：

来源：

Reactions Weekly | 2020年 / 1787卷 / 1期

关键词：

D O I：

10.1007/s40278-020-74056-8

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：418 / 418

相关论文

共 50 条

[21] Erlotinib/osimertinibDrug resistance: 3 case reports [J].

Reactions Weekly, 2021, 1874 (1) :106-106

[22] AntiviralsDevelopment of drug resistance: 3 case reports [J].

Reactions Weekly, 2020, 1809 (1) :46-46

[23] Cetuximab/imatinib/sunitinibAcquired resistance: 3 case reports [J].

Reactions Weekly, 2022, 1932 (1) :177-177

[24] Afatinib/gefitinib/osimertinibDrug resistance: 3 case reports [J].

Reactions Weekly, 2019, 1773 (1) :18-18

[25] Gefitinib/osimertinibAcquired drug resistance: 3 case reports [J].

Reactions Weekly, 2023, 1948 (1) :215-215

[26] Cefalexin/ertapenem/tetracyclineAcquired resistance: 3 case reports [J].

Reactions Weekly, 2022, 1935 (1) :133-133

[27] Multiple drugsAcquired drug resistance: 3 case reports [J].

Reactions Weekly, 2024, 2035 (1) :292-292

[28] AntineoplasticsLack of efficacy and drug resistance: 3 case reports [J].

Reactions Weekly, 2022, 1920 (1) :57-57

[29] PropranololVarious toxicities and acquired resistance: 3 case reports [J].

Reactions Weekly, 2015, 1578 (1) :251-251

[30] Pertuzumab/trastuzumabAcquired drug resistance: 3 case reports [J].

Reactions Weekly, 2019, 1778 (1) :377-377

← 1 2 3 4 5 →